The immunotherapy of Guillain-Barré syndrome

Introduction: Guillain-Barré syndrome is the most common cause of acute flaccid paralysis worldwide. Microorganisms such as Campylobacter jejuni, Cytomegalovirus, Epstein-Barr virus, Mycoplasma pneumoniae, Haemophilus influenzae and Zika virus have been linked to the disease. The most common clinica...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2018

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/24040

Acceso en línea:

https://doi.org/10.1080/14712598.2018.1468885
https://repository.urosario.edu.co/handle/10336/24040

Palabra clave:

Bisphosphonic acid derivative
Brain derived neurotrophic factor
Complement
Corticosteroid
Coversin
Cyclophosphamide
Eculizumab
Human soluble complement receptor type 1
Immunoglobulin
Interferon
Mirococept
Mycophenolate mofetil
Nafamstat mesilate
Protein
Rev 576
Rituximab
Unclassified drug
Immunologic factor
Analgesia
Cerebrospinal fluid filtration
Clinical decision making
Embase
Guillain barre syndrome
Human
Immunotherapy
Information retrieval
Intensive care unit
Medline
Pathophysiology
Pharmaceutical care
Plasma exchange
Review
Disease exacerbation
Guillain barre syndrome
Immunology
Immunotherapy
Plasmapheresis
Procedures
Disease progression
Guillain-barre syndrome
Humans
Immunologic factors
Immunotherapy
Plasma exchange
Plasmapheresis
Biological therapy
Complement
Guillain-barré syndrome
Immunotherapy
Intravenous immunoglobulins
Plasma exchange
Polyneuropathy
intravenous
Immunoglobulins

Rights

License

Abierto (Texto Completo)